ITC Judge Takes Notice of PTAB Institution Denials
By Matt Johnson PTAB trials are nearly always (~ 4 out of 5) driven by some concurrent litigation need, either a district court complaint of infringement filed against the petitioner or an International Trade Commission (ITC) investigation initiated by the patent...
Beware Of Relying on Your Confidential Information
By Dave Maiorana If you are involved in an IPR and you are contemplating whether to rely on your own confidential information as part of a filing, you need to consider the risk that the Board will deny your motion to file under seal because it relied on that...
PTAB Grants Motion to Amend Claims, Kind Of
By Lisamarie LoGiudice, Ph.D. and J. Patrick Elsevier, Ph.D. In Amerigen Pharmaceuticals Limited v. Shire LLC, IPR2015-02009 (March 31, 2017), the PTAB granted Shire’s Motion to Amend the claims in U.S. Reissued Patent RE 42,096, listed in the FDA’s Orange Book as...
En Banc Federal Circuit Considering Whether 1-Year IPR Time Bar Is Appealable
By John Marlott As we reported earlier, the Federal Circuit decided in January 2017 to rehear en banc whether the PTAB’s findings regarding 35 U.S.C. § 315(b)’s one year bar can be reviewed on appeal. Wi-Fi One v. Broadcom Corp. The Federal Circuit directed the...
PTAB Invalidates Two Anacor KERYDIN® Patents
By Olga Schwier, Ph.D. and Cary Miller, Ph.D. The PTAB found obvious all claims of U.S. Patent Nos. 7,582,621 and 7,767,657 in the three final written decisions issued on February 23, 2017 (IPR2015-01776, IPR2015-01780, and IPR2015-01785). This marks another victory...